Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

02 Jul, 2019, 08:12 BST Bioinvent Receives Ind Approval For Phase I/iia Trial of Anti-fcγriib Antibody

BioInvent International AB (BINV) today announces it has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an...


01 Jul, 2019, 07:00 BST New Research Reveals People With Hidden Health Conditions Like PKU Are 42% More Likely to Find Major Life Milestones Stressful

Phenylketonuria (PKU) is a rare, lifelong metabolic condition which limits a person's ability to break down protein, with devastating effects on the...


28 Jun, 2019, 14:40 BST New Study Shows that Nut Consumption May Help Improve Erectile Function

A recent study, partially supported by the INC and published in the journal Nutrients1, observed a significant increase in erectile function after...


28 Jun, 2019, 08:00 BST Menarini Ricerche Announces Publication of Pre-clinical Data of the First-in-class Antibody-drug Conjugate MEN1309/OBT076, Currently in Phase I Clinical Development

Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205...


27 Jun, 2019, 09:00 BST Saluda Medical Secures Debt Financing From Medtronic

Saluda Medical Pty Limited ("Saluda Medical") today announced that it has secured a four-year term loan agreement with Medtronic, to fund continued...


27 Jun, 2019, 09:00 BST Oxthera Presents Continuous Strong Data From an Interim Analysis of Its Phase 2 Study With Oxabact in Primary Hyperoxaluria

OxThera AB, a privately-held biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria (PH), today...


26 Jun, 2019, 08:51 BST InDex Pharmaceuticals Enrolls Last Patient in Phase IIb Study CONDUCT With Cobitolimod

InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is...


20 Jun, 2019, 16:20 BST Orion Biotechnology Reports Additional Positive Preclinical Data for OB-002 in the Treatment of Colorectal Cancer

Orion Biotechnology Canada Ltd., today announced new preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in colorectal cancer. BALB/c...


20 Jun, 2019, 14:00 BST Syqe Medical Receives Regulatory Approval to Release World's First Drug Delivery Device for Precise Dosing of Cannabis

Syqe Medical, a leading pharma-tech company, today announced the launch of the world's first pharmaceutical-grade metered-dose cannabis inhaler in...


20 Jun, 2019, 13:00 BST Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine

Definiens, a leading international Artificial Intelligence (AI)–based biomarker analysis and advanced data mining provider for immuno-oncology...


20 Jun, 2019, 12:17 BST Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus (NASDAQ STO: CAMX), a commercial stage biopharmaceutical company specializing in long-acting medicines for severe and chronic disorders,...


20 Jun, 2019, 11:50 BST Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS

Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company starts its first-in-human, phase I, clinical trial with...


20 Jun, 2019, 09:00 BST OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria

OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first...


19 Jun, 2019, 19:05 BST First-ever successful mind-controlled robotic arm without brain implants

A team of researchers from Carnegie Mellon University, in collaboration with the University of Minnesota, has made a breakthrough in the field of...


18 Jun, 2019, 15:26 BST Alligator Bioscience Submits Clinical Trial Application for ATOR-1017

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy,...


18 Jun, 2019, 13:37 BST Arix Bioscience plc: Imara Presents initial Phase 2a data for IMR-687

Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing and building breakthrough biotech companies, notes...


18 Jun, 2019, 13:00 BST Daiichi Sankyo's VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the Ministry of Health, Labor and Welfare (MHLW) of Japan has...


18 Jun, 2019, 07:20 BST Beactica Wins Grant to Develop Combination Therapy for Glioblastoma

Beactica AB, the Swedish drug discovery company, today announced that it has been awarded a grant of 2.8 MSEK (~$300 000) from SweLife and...


17 Jun, 2019, 13:30 BST Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials...


17 Jun, 2019, 13:00 BST Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as...


17 Jun, 2019, 07:30 BST Elthera Awarded 2.5 M €Grant From Horizon 2020 Program

Elthera is pleased to announce that it has been awarded 2.5 M € through the Horizon 2020 programme. Horizon 2020 is the financial instrument...


16 Jun, 2019, 15:09 BST New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial....


14 Jun, 2019, 11:40 BST BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy

BerGenBio ASA (OSE:BGBIO) today presents data showing significant efficacy in a Phase II clinical trial (BGBC003, NCT02488408) evaluating...


14 Jun, 2019, 09:20 BST New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in...


13 Jun, 2019, 12:30 BST GT BIOPHARMA GTB-1550 Multi-Targeted Bispecific Drug Conjugate Strategically Positioned in New Class of ADC Drugs

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company developing GTB-1550, a novel multi-target bispecific drug conjugate therapy for ...